Delving into the Latest Updates on UCB Celltech with Synapse

Overview

This is a Phase 2, multicenter, double-blind, placebo-controlled, 12-week proof-of-concept study to assess the efficacy, safety, and tolerability of UCB5857 in subjects with primary Sjögren's Syndrome (pSS).
The primary objective of this study is to evaluate the efficacy on overall disease activity and safety of UCB5857 added to current treatment relative to placebo in subjects with pSS.

Start Date01 Oct 2015

Sponsor / Collaborator

UCB Celltech

[+1]

100 Clinical Results associated with UCB Celltech

Login to view more data

0 Patents (Medical) associated with UCB Celltech

Login to view more data

416

Literatures (Medical) associated with UCB Celltech

31 Dec 2024·Journal of Medical Economics

The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland

Article

Author: Lyris, Nikos ; Rose, Micah ; Taieb, Vanessa ; Mørup, Michael F ; Willems, Damon ; Gerlier, Laetitia ; Lamotte, Mark ; Thom, Howard

OBJECTIVETo estimate the cost-effectiveness of a treatment-pathway initiated with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, in patients with axial spondyloarthritis (axSpA) compared with IL-17Ai's, ixekizumab, and secukinumab, from the NHS Scotland perspective.METHODSThe axSpA treatment-pathway was modeled using a decision tree followed by a lifetime Markov model. The pathway included first- and second-line biologic disease-modifying antirheumatic drugs (bDMARD), followed by best supportive care (bDMARD, nonbiologic). Bimekizumab followed by any bDMARD ("BKZ") was compared with IL-17Ai's: secukinumab 150 mg followed by a blend ("SEC") of dose up-titration to secukinumab 300 mg and any bDMARD, or ixekizumab followed by any bDMARD ("IXE"). Transition to the next therapy was triggered by Bath Ankylosing Spondylitis Disease Activity Index-50% (BASDAI50) non-response or any-cause discontinuation. A published network meta-analysis provided efficacy data. EuroQoL-5-dimensions utilities were derived by mapping from Ankylosing Spondylitis Disease Activity Score. Costs included disease management (linked to functional limitations), biologics acquisition (list prices), administration and monitoring (NHS 2021/22). Discounting was 3.5%/year. Probabilistic results from patients with non-radiographic axSpA and ankylosing spondylitis were averaged to reflect the axSpA disease spectrum. Scenario and sensitivity analyses were performed.RESULTSThe incremental cost-effectiveness ratio (ICER) of BKZ was £24,801/quality-adjusted life-year (QALY) vs. SEC (95% credible interval £24,163-£25,895). BKZ had similar costs (Δ -£385 [-£15,239-£14,468]) and QALYs (Δ 0.039 [-0.748-0.825]) to IXE, with £1,523 (£862-£2,222) net monetary benefit. Conclusions remained unchanged in most scenarios. Results' drivers included BASDAI50 response rate and disease management cost.LIMITATIONSResults were based on list prices. Data concerning up-titration to secukinumab 300 mg was scarce.CONCLUSIONSThe bimekizumab treatment-pathway represents a cost-effective option across the axSpA disease spectrum in Scotland. Bimekizumab is cost-effective compared to a secukinumab-pathway that includes dose up-titration, and has similar costs and QALYs to an ixekizumab-pathway.

31 Dec 2024·Bioengineered

Chimeric antigens displaying GPR65 extracellular loops on a soluble scaffold enabled the discovery of antibodies, which recognized native receptor

Article

Author: Barrett, Janine ; Al-Mossawi, Hussein ; Lawson, Alastair D G ; Leysen, Seppe ; Edwards, Thomas E ; Bowness, Paul ; Galmiche, Cécile

GPR65 is a proton-sensing G-protein coupled receptor associated with multiple immune-mediated inflammatory diseases, whose function is relatively poorly understood. With few reagents commercially available to probe the biology of receptor, generation of an anti-GPR65 monoclonal antibody was desired. Using soluble chimeric scaffolds, such as ApoE3, displaying the extracellular loops of GPR65, together with established phage display technology, native GPR65 loop-specific antibodies were identified. Phage-derived loop-binding antibodies recognized the wild-type native receptor to which they had not previously been exposed, generating confidence in the use of chimeric soluble proteins to act as efficient surrogates for membrane protein extracellular loop antigens. This technique provides promise for the rational design of chimeric antigens in facilitating the discovery of specific antibodies to GPCRs.

01 Nov 2024·Journal of Investigative Dermatology

Crystal Structure of Bimekizumab Fab Fragment in Complex with IL-17F Provides Molecular Basis for Dual IL-17A and IL-17F Inhibition

Article

Author: Lawson, Alastair D G ; Adams, Ralph ; Shaw, Stevan ; Gomez, Braulio ; Bunick, Christopher G

A review.Psoriasis (PSO) and psoriatic arthritis are T helper 17-driven inflammatory diseases where interleukin-17 cytokines such as IL-17A and IL-17F promote disease pathogenesis.In contrast to these therapies, bimekizumab (BKZ) is a novel humanized IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A with binding affinities of 23 and 3.2 pM, resp.The clin. efficacy of BKZ warrants increased utility in patients with PSO, thereby necessitating a deeper mol. understanding of its mechanism of action.These data provide supportive evidence linking the unique structural features of BKZ with the deep and sustained clin. response observed in patients with PSO and psoriatic arthritis.

100 Deals associated with UCB Celltech

Login to view more data

100 Translational Medicine associated with UCB Celltech

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

14

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

KIM-127 ( CD18 )	Inflammation More	Discontinued
Seletalisib ( PI3Kδ )	Primary Sjögren's syndrome More	Discontinued
CH-928 ( PDE4 )	Asthma More	Discontinued
CH-104 ( MMPs )	Neoplasms More	Discontinued
CDP-492	Vomiting More	Discontinued